The estimated Net Worth of Thomas Sciascia is at least $1.57 Milion dollars as of 19 August 2024. Thomas Sciascia owns over 16,496 units of Trevi Therapeutics stock worth over $781,476 and over the last 5 years he sold TRVI stock worth over $0. In addition, he makes $786,845 as Co-Founder a Chief Medical Officer at Trevi Therapeutics.
Thomas has made over 3 trades of the Trevi Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 16,496 units of TRVI stock worth $23,589 on 19 August 2024.
The largest trade he's ever made was exercising 59,354 units of Trevi Therapeutics stock on 29 May 2024 worth over $129,985. On average, Thomas trades about 8,946 units every 7 days since 2019. As of 19 August 2024 he still owns at least 236,811 units of Trevi Therapeutics stock.
You can see the complete history of Thomas Sciascia stock trades at the bottom of the page.
Dr. Thomas R. Sciascia M.D. serves as Co-Founder, Chief Medical Officer of the Company. Dr. Sciascia is our co-founder, and has served as our Chief Medical Officer since our inception in March 2011. Previously, Dr. Sciascia was the Senior Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest from 2001 to 2010. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. from 1997 to 2000 as a consultant to pharmaceutical and biotechnology companies. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc) from 2000 to 2001. Dr. Sciascia received a B.S. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. He is a board-certified neurologist licensed to practice medicine in the state of Massachusetts.
As the Co-Founder a Chief Medical Officer of Trevi Therapeutics, the total compensation of Thomas Sciascia at Trevi Therapeutics is $786,845. There are 1 executives at Trevi Therapeutics getting paid more, with Jennifer Good having the highest compensation of $2,810,720.
Thomas Sciascia is 65, he's been the Co-Founder a Chief Medical Officer of Trevi Therapeutics since 2011. There are 3 older and 14 younger executives at Trevi Therapeutics. The oldest executive at Trevi Therapeutics, Inc. is Anne VanLent, 72, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510.
Over the last 5 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett a Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics executives and other stock owners filed with the SEC include: